z-logo
open-access-imgOpen Access
General Considerations on Clinical Trials of Hemophilia Medicines
Author(s) -
Ж И Авдеева,
А. А. Солдатов,
В. П. Бондарев,
В. А. Меркулов
Publication year - 2020
Publication title -
biopreparaty. profilaktika, diagnostika, lečenie
Language(s) - English
Resource type - Journals
eISSN - 2619-1156
pISSN - 2221-996X
DOI - 10.30895/2221-996x-2020-20-1-30-41
Subject(s) - clinical trial , medicine , guideline , orphan drug , authorization , marketing authorization , intensive care medicine , coagulation , disease , agency (philosophy) , bioinformatics , pathology , philosophy , computer security , epistemology , computer science , biology
Hemophilia is an orphan disease associated with deficiency or complete lack of certain blood coagulation factors due to mutation of genes encoding their synthesis. Patients with hemophilia need continuous replacement therapy with coagulation factor products which are produced by recombinant DNA technology or derived from donated blood plasma. The development of new products or improvement of the production process of already authorised medicinal products involve clinical trials that have to include both previously treated and untreated patients of different age groups. The aim of the paper was to perform an analytical review of general hemophilia issues and major requirements for clinical trials of coagulation factor IX products based on the updated documents of the European Medicines Agency. The paper summarises the basic principles of conducting clinical trials of coagulation factor IX products that are submitted for marketing authorisation as “new” products, based on recommendations of Russian and international regulatory documents, including the updated guideline of the European Medicines Agency. It sums up product safety issues associated with undesirable immunogenicity resulting in formation of inhibitors that provoke allergic reactions or reduce the effectiveness of therapy. The harmonisation of the requirements for clinical trials during preparation and updating of documents by Russian manufacturers should be based on the analysis of the experience with hemophilia products and latest scientific achievements in the disease treatment. In that case it will facilitate the introduction of innovative efficacious hemophilia products into clinical practice.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here